Edition:
India

Elanco Animal Health Inc (ELAN.N)

ELAN.N on New York Stock Exchange

21.55USD
7 Jul 2020
Change (% chg)

$-0.21 (-0.97%)
Prev Close
$21.76
Open
$21.60
Day's High
$21.82
Day's Low
$21.28
Volume
2,137,953
Avg. Vol
1,226,373
52-wk High
$35.23
52-wk Low
$15.17

Summary

Name Age Since Current Position

R. David Hoover

74 2018 Independent Chairman of the Board

Jeffrey Simmons

52 2018 President, Chief Executive Officer, Director

Todd Young

48 2018 Chief Financial Officer, Executive Vice President

Michael-Bryant Hicks

45 2018 Executive Vice President, General Counsel, Corporate Secretary

David Kinard

53 2019 Executive Vice President of Human Resources

Sarena Lin

49 2019 Executive Vice President, Global Marketing, Corporate Strategy and Transformation

Ramiro Cabral

48 2019 Executive Vice President - Elanco International

Aaron Schacht

52 2018 Executive Vice President - Innovation, Regulatory, Business Development

David Urbanek

53 2018 Executive Vice President - Manufacturing, Quality

James Meer

50 2018 Chief Accounting Officer, Vice President

Kapila Anand

66 2018 Independent Director

John Bilbrey

63 2019 Independent Director

Art Garcia

59 2019 Independent Director

Michael Harrington

57 2018 Independent Director

Deborah Kochevar

63 2019 Independent Director

Lawrence Kurzius

62 2018 Independent Director

Kirk McDonald

53 2019 Independent Director

Carl McMillian

52 Independent Director

David Ricks

51 Independent Director

Denise Scots-Knight

60 2019 Independent Director

Aarti Shah

55 Independent Director

Joshua Smiley

50 Independent Director

Biographies

Name Description

R. David Hoover

Mr. R. David Hoover is Independent Chairman of the Board of the Company. Mr. Hoover has served as the chairman of the Board since May 2018. Mr. Hoover has been retired since 2013. Prior to that, Mr. Hoover served in various roles at Ball Corporation, a company supplying innovative, sustainable packaging solutions and other technologies and services, including Chairman from 2002 to 2013, Chief Executive Officer from 2010 to 2011, President and Chief Executive Officer from 2001 to 2010, Chief Operating Officer from 2000 to 2001 and Chief Financial Officer from 1998 to 2000. Mr. Hoover currently serves on the board of directors of Edgewell Personal Care Company and has previously served on the board of directors of Ball Corporation and of Lilly. Mr. Hoover’s experience described above, including his extensive management experience as Chief Executive Officer and Chief Financial Officer at Ball Corporation and corporate governance experience through his service on other public boards, including nine years he previously served as a director for Lilly, provides him with the qualifications and skills to serve as a director on Elanco’s Board.

Jeffrey Simmons

Mr. Jeffrey N. Simmons is the President, Chief Executive Officer and Director of the Company. Mr. Simmons as served as Elanco’s President and Chief Executive Officer and as a member of the Board since July 2018. Mr. Simmons served as the President of the Elanco Animal Health division of Lilly and Senior Vice President of Lilly from 2008 until September 2018. Prior to 2008, Mr. Simmons held various leadership roles for Elanco, including District Sales Manager, International Marketing Manager, Country Director for Brazil, Area Director for Western Europe and Executive Director for U.S. and Global Research & Development. Mr. Simmons’ experience described above, including his knowledge of Elanco and the animal health industry and his business and management experience, provides him with the qualifications and skills to serve as a director on Elanco’s Board.

Todd Young

Mr. Todd S. Young is Chief Financial Officer, Executive Vice President of the Company. Prior to joining Elanco, Mr. Young was the Executive Vice President and Chief Financial Officer at ACADIA Pharmaceuticals, a biopharmaceutical company, since 2016. Prior to his time at ACADIA, Mr. Young served as Senior Vice President and Treasurer leading the creation of a capital structure for Baxalta, a biopharmaceutical company, up until its acquisition by Shire in June 2016. Prior to Baxalta, Mr. Young worked for over 14 years at Baxter International Inc., a health care company, in multiple leadership roles, including Corporate Vice President and Treasurer, Vice President, International Finance, and Vice President, Global Financial Planning and Analysis.

Michael-Bryant Hicks

Mr. Michael-Bryant Hicks serves as Executive Vice President, General Counsel, Corporate Secretary of the Company. Mr. Hicks served as General Counsel of the Elanco Animal Health division of Lilly from May 2018 to September 2018. Prior to joining Elanco, Mr. Hicks served in various legal roles, including General Counsel at Mallinckrodt plc, a specialty pharmaceutical company, from 2016 to 2018, Senior Vice President, General Counsel and Corporate Strategy at The Providence Service Corporation, a social services company, from 2014 to 2016 and as Assistant General Counsel at DaVita Inc., a health care company, from 2011 to 2013.

David Kinard

Mr. David S. Kinard is Executive Vice President of Human Resources of the Company. Mr. Kinard served as Elanco’s Executive Vice President, Human Resources and Corporate Affairs from July 2018 to December 2018, and as Vice President of Human Resources and Global Learning and Development for the Elanco Animal Health division of Lilly from May 2018 to September 2018. Prior to May 2018, Mr. Kinard served in various leadership roles for Lilly, including Vice President of Human Resources for a variety of Lilly businesses, including Lilly International in 2017, Bio-Medicines and Emerging Markets from 2015 to 2017, and Lilly Diabetes and Global Employee Relations/HR Operations from 2011 to 2015.

Sarena Lin

Ms. Sarena S. Lin serves as Executive Vice President, Global Marketing, Corporate Strategy and Transformation of the Company. Ms. Lin served as Executive Vice President, Elanco USA, Corporate Strategy and Global Marketing from January 2019 to October 2019, as Executive Vice President, Elanco USA and Global Strategy from July 2018 to December 2018 and as Senior Vice President of North American Operations and Strategy at the Elanco Animal Health division of Lilly from January 2018 to September 2018. Prior to joining Lilly, Ms. Lin served as President of Cargill Feed & Nutrition, an animal nutrition company, from 2014 to 2017. Prior to 2014, Ms. Lin served as Global Head of Strategy and Business Development for Cargill from 2011 to 2014, leading major strategy and acquisitions. Prior to 2011, Mr. Lin was a partner at McKinsey, specializing in cross-border strategy and large scale post-merger integrations. Ms. Lin served on the board of directors for the animal health and dental distributor, Patterson Companies, from 2014 to 2018.

Ramiro Cabral

Mr. Ramiro M. Cabral is Executive Vice President - Elanco International of the Company. Mr. Cabral served as Executive Vice President, Elanco International and Global Customer Value from July 2018 to December 2018, and as Vice President and Chief Marketing Officer of the Elanco Animal Health division of Lilly from 2017 until September 2018. Mr. Cabral joined Lilly in 2005 and held various leadership positions for Elanco, including Vice President and Head of Operations for Elanco EMEA from 2013 to 2017, during the acquisitions and integrations of Janssen, Lohmann and Novartis Animal Health divisions. Mr. Cabral’s other roles include Senior Director, U.S. Beef Business Unit from 2011 to 2012, General Manager of Elanco Canada from 2008 to 2010, and Global Marketing Manager from 2005 to 2007.

Aaron Schacht

Mr. Aaron L. Schacht serves as Executive Vice President - Innovation, Regulatory, Business Development of the Company. Mr. Schacht served as the Vice President of global research and development of the Elanco Animal Health division of Lilly from 2015 to September 2018. Prior to 2015, Mr. Schacht served in various leadership roles for Lilly, including Global Brand Development Leader of Pain in Lilly BioMedicines in 2014, Senior Advisor of Strategy & Business Development for Lilly BioMedicines from 2012 to 2014, and Executive Director of Global External R&D at Lilly from 2008 to 2012.

David Urbanek

Mr. David A. Urbanek serves as Executive Vice President - Manufacturing, Quality of the Company. Mr. Urbanek served as Vice President of Manufacturing at the Elanco Animal Health division of Lilly from November 2017 to September 2018. Prior to that, Mr. Urbanek served in various leadership roles for Lilly’s Manufacturing division, including Senior Director of Emerging Markets Manufacturing from 2013 to 2017, Senior Director of Global Diabetes Manufacturing from 2011 to 2013, and Senior Director of External Drug Products Operations from 2009 to 2011.

James Meer

Mr. James M. Meer serves as Chief Accounting Officer, Vice President of the Company. Prior to joining Elanco, Mr. Meer served as the Chief Financial Officer of Healthx, Inc., a healthcare technology company beginning June 2017. Prior to joining Healthx, he served as Senior Vice President of Finance at Appirio, an information technology consulting company, from 2014 to 2017, and as Vice President and Corporate Controller at Salesforce (previously ExactTarget), a cloud-based software company, from 2011 to 2014. Prior to 2011, Mr. Meer held various financial, accounting and strategy positions at 3M (previously Aero Technologies Inc.), Hill-Rom, Hillenbrand Industries and Ernst & Young LLP.

Kapila Anand

Ms. Kapila K. Anand is an Independent director of the Company. Ms. Anand is a C.P.A. and has served as a Senior Advisor to KPMG LLP, an accounting firm, since 2016. Prior to that, Ms. Anand served in various leadership roles as a partner at KPMG LLP, including Industry Segment Leader - Travel, Leisure and Hospitality from 2011 to 2017, Partner in Charge - Public Policy Business Initiatives from 2009 to 2013, KPMG LLP Board member from 2005 to 2010, Advisory Leader - Private Equity, Real Estate and Hospitality from 2002 to 2009 and Audit Partner - Real Estate and Hospitality from 1989 to 2002. Ms. Anand currently serves as a member of the board of directors of Extended Stay America, Inc. and Omega Healthcare Investors, Inc.

John Bilbrey

Mr. John P. Bilbrey is Independent Director of the company. He served as the CEO and President of The Hershey Company, a multinational consumer food company, from 2011 until his retirement in 2017, and as Chairman of the Board from 2015 until 2018. Previously, Bilbrey served in various roles at The Hershey Company, including as the Chief Operating Officer and EVP from 2010 to 2011, the President of North America from 2007 to 2010, the President of International Commercial group from 2005 to 2007. Prior to joining The Hershey Company, he held leadership positions at Mission Foods, Danone Waters of North America, Inc., Bilbrey Farms and Ranch and Procter & Gamble Company. Mr. Bilbrey currently serves on the board of directors of Colgate-Palmolive Company and Campbell Soup Company, and has previously served on the boards of directors of The Hershey Company and McCormick & Company, Incorporated.

Art Garcia

Mr. Art A. Garcia CPA serves as Independent Director of the Company. Mr. Garcia served in various leadership roles at Ryder System, Inc., an American provider of transportation and supply chain management products, and is especially known for its fleet of rental trucks (“Ryder’’). At Ryder, Mr. Garcia held the positions of Executive Vice President and Chief Financial Officer from 2010 until his retirement in April 2019, Senior Vice President and Controller from 2005 to 2010, and Vice President and Controller from 2002 to 2005, Mr. Garcia is a certified public accountant. Mr. Garcia currently serves on the board of directors of ABM Industries Incorporated and American Electric Power.

Michael Harrington

Mr. Michael J. Harrington serves as Independent Director of the Company. Mr. Harrington served in various legal roles for Lilly, including Senior Vice President and General Counsel from 2013 until his retirement in January 2020, Vice President and Deputy General Counsel of Global Pharmaceutical Operations from 2010 to 2012 and Vice President and General Counsel, Corporate from 2004 to 2010. Mr. Harrington’s roles at Lilly have provided him with extensive business development experience, experience with regulatory agencies around the world, and experience with managing intellectual property matters globally. In addition, Mr. Harrington has global operations and leadership experience as he led one of Lilly’s operating affiliates in New Zealand, and has had other leadership roles in the Asia Pacific region. In addition, Mr. Harrington has led Lilly’s information security program, and has experience with negotiating transitional services agreements (TSAs), and experience with the oversight of implementing enterprise resource planning (ERP) systems. Mr. Harrington has also had oversight of Lilly’s enterprise risk management (ERM) program. Mr. Harrington’s experience described above, including his knowledge of Elanco and the animal health industry, provides him with the qualifications and skills to serve as a director on Elanco’s Board.

Deborah Kochevar

Dr. Deborah Turner Kochevar is Independent Director of the company. Dr. Kochevar is a Senior Fellow at Fletcher School of Law and Diplomacy, and Dean Emerita of Cummings School of Veterinary Medicine at Tufts University. Dr. Kochevar served as the Provost and Senior Vice President ad interim at Tufts University from 2018-2019. She served as the Dean of the Cummings School of Veterinary Medicine at Tufts University from 2006 through 2018. Previously, Dr. Kochevar was a long-time faculty member and administrator at the College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, where she held the Wiley Chair of Veterinary Medical Education. Dr. Kochevar is a past-president of the Association of American Veterinary Medical Colleges and American College of Veterinary Clinical Pharmacology. Dr. Kochevar is active in the American Veterinary Medical Association, having chaired its Council on Education and the Educational Commission for Foreign Veterinary Graduates. Dr. Kochevar currently serves on the board of directors of Charles River Laboratories International, Inc.

Lawrence Kurzius

Mr. Lawrence Erik. Kurzius is an Independent Director of the Company. Mr. Kurzius has served in various leadership roles at McCormick & Company, a global food company, including director since 2015 and Chairman of the Board of Directors since 2017, Chief Executive Officer since 2016, President since 2015, Chief Operating Officer from 2015 to 2016, Chief Administrative Officer from 2013 to 2015, President, International Businesses from 2008 to 2013, President, Europe, Middle East and Africa from 2007 to 2008 and President, U.S. Consumer Foods from 2005 to 2006.

Kirk McDonald

Mr. Kirk McDonald serves as Independent Director of the Company. Mr. McDonald has served as the Chief Business Officer of Xandr, AT&T’s advertising company, since September 2019, and from 2017, has served as Xandr’s the Chief Marketing Officer. Prior to Xandr, from 2011 to 2017, Mr. McDonald served as the President of PubMatic, a company developing and implementing online advertising software and strategies. Before joining PubMatic, he was President of Digital at Time Inc., from 2009 to 2011, and the Chief Advertising Officer of the Fortune|Money Group. He has also served as the SVP of Sales, Marketing and Client Services for DRIVEpm and Atlas, both units of Microsoft’s advertising business, as well as in various roles at CNET, Ziff Davis and Condé Nast. McDonald serves on several professional and not-for-profit boards. He was a former advisor on the LUMA Partners board and is currently the Chairman of a non-profit, Code Interactive, which is focused on inspiring the next generation of technology leaders from underserved communities.

Carl McMillian

Mr. Carl L. McMillian serves as Independent Director of the Company. Mr. McMillian has served as Vice President of Toxicology, Drug Disposition, PKPD, Veterinary Resources & Experimental Medicine of Lilly since 2012. Prior to that, Mr. McMillian served in various leadership roles for Lilly, including Senior Director, Drug Disposition from 2008 to 2012 and Director, Drug Disposition from 2002 to 2008.

David Ricks

Mr. David A. Ricks serves as Independent Director of the Company. Mr. Ricks has served as the Chief Executive Officer and President of Lilly since January 2017; Mr. Ricks joined the board of Lilly in January 2017 and became Chairman in June 2017. Prior to that, Mr. Ricks served in various leadership roles for Lilly, including President of Lilly Bio-Medicines from 2012 to 2016 and President of Lilly USA from 2009 to 2012.

Denise Scots-Knight

Dr. Denise Scots-Knight is Independent Director of the company. Dr. Scots-Knight was the co-founder of, and has served as the Chief Executive Officer and member of the board of Mereo BioPharma Group plc, a specialty biopharmaceutical Company, since 2015. From 2010 until 2015, she was the Managing Partner of Phase4 Partners Ltd., a global life science venture capital firm. From 2004 to 2010, Dr. Scots-Knight was head of Nomura Phase4 Ventures, a venture capital affiliate of Nomura International plc, a leading Japanese financial institution. Dr. Scots-Knight has served on the boards of directors of Oncomed Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc. and Nabriva Therapeutics AG. Ms. Scots-Knight’s experience described above, including her extensive previous board leadership, history leading an innovation and growth-oriented company, and expertise building innovation models and partnerships, provides her with the qualifications and skills to serve as a director on Elanco’s Board.

Aarti Shah

Ms. Aarti Shah Ph.D. serves as Independent Director of the Company. Ms. Shah has served as Senior Vice President and Chief Information Officer of Lilly since July 2016. Prior to that, Ms. Shah served in various leadership roles for Lilly, including Global Brand Leader of the Autoimmune Division of Lilly Bio-Medicines from 2013 to 2016 and Vice President of Biometrics & Advanced Analysis from 2009 to 2013. Ms. Shah's experience described above, including her knowledge of our company and the animal health industry and her business and management experience, provides her with the qualifications and skills to serve as a director on our board.

Joshua Smiley

Mr. Joshua L. Smiley serves as Independent Director of the Company. Mr. Smiley has served as Senior Vice President and Chief Financial Officer of Lilly since January 2018. Prior to January 2018, Mr. Smiley held a variety of leadership positions at Lilly, including Senior Vice President and Treasurer in 2017 and Senior Vice President of Finance, Corporate Controller and Chief Financial Officer of Lilly Research from 2011 to 2015. Mr. Smiley's experience described above, including his knowledge of our company and the animal health industry and his business and management experience, provides him with the qualifications and skills to serve as a director on our board.